Filing Details

Accession Number:
0000921895-23-000200
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-26 13:05:33
Reporting Period:
2023-01-24
Accepted Time:
2023-01-26 13:05:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
910267 Titan Pharmaceuticals Inc TTNP Biological Products, (No Disgnostic Substances) (2836) 943171940
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1817604 Activist Investing Llc 1185 Avenue Of The Americas, 3Rd Floor.
New York NY 10036
No No No Yes
1932843 E. David Lazar Villa 1, 14-43Rd Street
Jumeirah 2
Dubai C0 00000
Chief Executive Officer Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.001 Acquisiton 2023-01-24 37,500 $0.97 3,368,902 No 4 P Direct
Common Stock, Par Value $0.001 Acquisiton 2023-01-25 20,000 $1.00 3,388,902 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, Par Value $0.001 359,066 Indirect By Activist Investing LLC
Footnotes
  1. Represents a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $0.9591 to $0.98. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote.
  2. This Form 4 is filed jointly by Activist Investing LLC ("Activist Investing") and David E. Lazar (collectively, the "Reporting Persons").
  3. Each Reporting Person disclaims beneficial ownership of the securities of the Issuer reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or any other purpose.
  4. Represents a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $0.97 to $1.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote.
  5. Securities of the Issuer beneficially owned directly by Activist Investing. Mr. Lazar, as the sole member and Chief Executive Officer of Activist Investing, may be deemed the beneficial owner of the securities of the Issuer beneficially owned by Activist Investing.